Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors

Oncotarget(2024)10.18632/oncotarget.28650Source: DataRank Database

Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors is a research paper published in Oncotarget (2024). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 0.81)OA: goldTopics (57)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Ellen Voigt ORCID,Dawn E. Quelle ORCID,Joshua J. Lingo ORCID

Live enrichment

PubMed:39347707 PMC:PMC11441412 OpenAlex:https://openalex.org/W4402966554

NCI NIH HHS

Grant: P30 CA086862

NCI NIH HHS

Grant: F31 CA281312

NINDS NIH HHS

Grant: R01 NS119322

NIGMS NIH HHS

Grant: T32 GM139776

National Institutes of Health

Grant: 5F31CA281312-02

Intratumoral plasma cells in MPNST response to CDK4/6 targeted therapy and sensitization to immune checkpoint blockade

National Institutes of Health

Grant: 1P30CA086862-01

Core--Clinical trials support group

National Institutes of Health

Grant: 5R01NS119322-04

Ink4a/ARF/Ink4b locus in Neurofibromatosis Type 1

FWCI

0.81

Citation Percentile

0.7%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://www.oncotarget.com/article/28650/pdf/

publisherhttps://www.oncotarget.com/article/28650/pdf/

publisherhttps://www.oncotarget.com/lookup/doi/10.18632/oncotarget.28650

journalhttps://doi.org/10.18632/oncotarget.28650

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39347707

Fields of Study

Neurofibromatosis and Schwannoma CasesCancer Mechanisms and TherapyNeuroblastoma Research and Treatments03 medical and health sciences0302 clinical medicineForkhead Box Protein M1HumansB7-H1 AntigenCyclin-Dependent Kinase 4AnimalsDrug Resistance, NeoplasmCyclin-Dependent Kinase 6Protein Kinase InhibitorsMiceMolecular Targeted TherapyNeurofibrosarcomaNerve Sheath Neoplasms

MeSH Terms

Forkhead Box Protein M1AnimalsHumansNerve Sheath NeoplasmsNeurofibrosarcomaDrug Resistance, NeoplasmProtein Kinase InhibitorsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6MiceMolecular Targeted TherapyB7-H1 Antigen

Keywords

FOXM1MedicineMalignant peripheral nerve sheath tumorPeripheralCancer researchTargeted therapyOncologyInternal medicineCancerCell cycleImmunohistochemistryPD-L1MpnstTherapy ResistanceCdk4/6-mek TargetingForkhead Box Protein M1Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Mini-ReviewB7-H1 AntigenNerve Sheath NeoplasmsMiceDrug Resistance, NeoplasmNeurofibrosarcomaHumansAnimalsMolecular Targeted TherapyProtein Kinase Inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being

Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors

FAIR Checklist

Authors (3)

Funding (7 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)